European Journal of Clinical Pharmacology

, Volume 49, Issue 4, pp 317–323

Increase in magnesium plasma level after orally administered trimagnesium dicitrate

  • C. Wilimzig
  • R. Latz
  • W. Vierling
  • E. Mutschler
  • T. Trnovec
  • S. Nyulassy
Pharmacokinetics And Disposition


Magnesium plasma concentrations were measured in healthy probands before and after administration of trimagnesium dicitrate by the oral and intravenous routes. There was a notable circadian fluctuation of the plasma concentration with a peak in the evening hours. After oral administration of 12 and 24 mmol magnesium, a long-lasting, statistically significant increase in plasma magnesium concentration measured as the increase in area under the curve (AUC) between 0 and 12 h, of 3.1% and 4.6%, respectively, was found. After intravenous administration of 4 and 8 mmol magnesium, AUCs increased by 9.5% and 16.1%, respectively. The decline in the plasma magnesium concentration after i.v. administration was compatible with a three-compartment model with a terminal half-time of about 8 h. Although no absolute value of the oral bioavailability of trimagnesium dicitrate could be determined from the data, our results may be important in helping to elucidate the influence of magnesium preparations on the plasma magnesium concentration. By comparing the effects of different preparations, it should be possible to estimate the relative oral bioavailability and the bioequivalence of these preparations.

Key words

Magnesium Plasma level pharmacokinetics bioavailability circadian fluctuation 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aikawa JK (1981) Magnesium. Its biologic significance. CRC Press, Boca Raton.Google Scholar
  2. Altura BT, Wilimzig C, Trnovec T, Nyalassy S, Altura BM (1995) Comparative effects of a Mg-enriched diet and different orally administered magnesium oxide preparations on ionized Mg, Mg metabolism and electrolytes in plasma of human volunteers. J Am Coll Nutr (in press).Google Scholar
  3. Antoni DH, Engel M, Gumpel N (1989) Die Therapie von supraventrikulären und ventrikulären Herzrhythmusstörungen mit Magnesium. Mag Bull 11:125–129.Google Scholar
  4. Blume H, Mutschler E (1991) Bioäquivalenz-Qualitätsbewertung wirkstoffgleicher Fertigarzneimittel, part 1/I. GOVI Press, Frankfurt.Google Scholar
  5. Chipperfield B, Chipperfield JR (1977) Magnesium and the heart. Am Heart J 93:679–682.CrossRefPubMedGoogle Scholar
  6. Danielson BG, Johansson G, Jung B, Ljunghall S, Lundquist H, Malmborg P (1979) Gastrointestinal magnesium absorption. Miner Electrolyte Metab 2:116–123.Google Scholar
  7. Dichtl A, Vierling W (1991) Inhibition by magnesium of calcium inward current in heart ventricular muscle. Eur J Pharmacol 204:243–248.CrossRefPubMedGoogle Scholar
  8. Douglas WW, Rubin RP (1963) The mechanism of catecholamine release from the adrenal medulla and the role of calcium in stimulus-secretion coupling. J Physiol 167:288–310.CrossRefPubMedCentralPubMedGoogle Scholar
  9. Ebel H, Günther T (1980) Magnesium metabolism: a review. J Clin Chem Clin Biochem 18:257–270.PubMedGoogle Scholar
  10. Ebel H, Classen H-G, Marquardt P, Späth M (1975) Zur Pharmakologie und Pharmakokinetik von Magnesium. Münch Med Wschr 117:1243–1248.Google Scholar
  11. Fehlinger R, Franke L, Glatzel E, Meyer E, Michalik M, Rapaport SM, Rüstow M, Schulz C, Schumann G (1981) Klinische Studien zur Mg-Behandlung des tetanischen Syndroms. Mag Bull 1a:298–306.Google Scholar
  12. Ghani MF, Rabah M (1977) Effect of magnesium chloride on electrical stability of heart. Am Heart J 94:600–602.CrossRefPubMedGoogle Scholar
  13. Hall SK, Fry CH (1992) Magnesium affects excitation, conduction, and contraction of isolated mammalian cardiac muscle. Am J Physiol 263:H622-H633.PubMedGoogle Scholar
  14. Holzgartner H, Maier E, Vierling W (1990) Hochdosierte orale Magnesiumtherapie bei Herzrhythmusstörungen. Fortschr Med 108:539–542.PubMedGoogle Scholar
  15. Iseri LT (1986) Magnesium and dysrhythmias. Mag Bull 8:223–229.Google Scholar
  16. Iseri LT, Freed J, Bures AR (1975) Magnesium deficiency and cardiac disorders. Am J Med 58:837–846.CrossRefPubMedGoogle Scholar
  17. ISIS-4 Collaborative Group (1995) ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 345:669–685.CrossRefGoogle Scholar
  18. Jahnen A, Hesse A (1990) Zur Verwertbarkeit von Magnesium aus verschiedenen Darreichungsformen. VitaMinSpur 5:34–39.Google Scholar
  19. Karbach U, Feldmeier H (1991) New clinical and experimental aspects of intestinal magnesium transport. Magnes Res 4:9–22.PubMedGoogle Scholar
  20. Lindberg JS, Lobitz MM, Poindexter JR, Pak CYC (1990) Magnesium bioavailability from magnesium citrate and magnesium oxide. J Am Coll Nutr 9:48–55.CrossRefPubMedGoogle Scholar
  21. Lücker PW, Nestler T (1985) Zur therapeutischen Verwertbarkeit von Magnesiumzubereitungen. Mag Bull 7:62–65.Google Scholar
  22. Meisinger V (1992) Magnesium und Laboranalytik. Mag Bull 14:1–5.Google Scholar
  23. Mühlbauer B, Schwenk M, Coram WM, Antonin KH, Etienne P, Bieck PR, Douglas FL (1991) Magnesium-L-aspartate-HCl and magnesium-oxide: bioavailability in healthy volunteers. Eur J Clin Pharmacol 40:437–438.CrossRefPubMedGoogle Scholar
  24. Nicar MHJ, Pak CYC (1982) Oral magnesium load test for the assessment of intestinal magnesium absorption. Miner Electrolyte Metab 8:44–51.PubMedGoogle Scholar
  25. Nowitzki-Grimm R, Grimm P, Thöni H, Classen HG (1991) Diagnosis of magnesium status. Mag Bull 13:107–115.Google Scholar
  26. Pflug B, Paschen A, Aigeldinger E (1979) Tagesrhythmische Schwankungen der Magnesiumkonzentration in Plasma und Erythrozyten. Krankenhausarzt 52:281–284.Google Scholar
  27. Schlebusch H, Pietrzik K, Gilles-Schmögner G, Zien A (1992) Bioverfügbarkeit von Magnesium als Magnesiumorotat und Magnesiumhydroxidcarbonat. Med Welt 43:532–528.Google Scholar
  28. Spätling L (1985) Magnesiummangel und vorzeitige Wehentätigkeit. Mag Bull 3:81–86.Google Scholar
  29. Szyska A, Brocki Z, Mrozikiewicz A, Paradowski S (1992) Dobowe zmiany stcezenia magnezu w surowicy zdrowych ludzi. Pol Tyg Lek 47:1078–1079.Google Scholar
  30. Teo KK, Yusuf S (1993) Role of magnesium in reducing mortality in acute myocardial infarction. Drugs 46:347–359.CrossRefPubMedGoogle Scholar
  31. Wilimzig C, Vierling W (1991) Hochdosierte orale Magnesium-Therapie bei Koronarer Herzerkrankung. Herz Gefäße 11:602–627.Google Scholar
  32. Woods KL, Fletcher S, Roffe C, Haider Y (1992) Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 339:1553–1558.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • C. Wilimzig
    • 1
  • R. Latz
    • 1
  • W. Vierling
    • 2
  • E. Mutschler
    • 3
  • T. Trnovec
    • 4
  • S. Nyulassy
    • 4
  1. 1.Datapharm GmbH, PlaneggMunichGermany
  2. 2.Pharmacological InstituteTechnical University of MunichMunichGermany
  3. 3.Pharmacological InstituteUniversity of Frankfurt, Biocenter NiederuselFrankfurt am MainGermany
  4. 4.Institute for Preventive and Clinical MedicineUniversity of BratislavaSlovak Republic

Personalised recommendations